[Edaily Reporter YU JIN-HEE ] As glucagon-like peptide-1 (GLP-1) class obesity and diabetes treatments have established themselves as a major trend in the global pharmaceutical and biotech markets, strong buying momentum is gathering in the domestic stock market around companies with related pipelines and infrastructure. On the 16th, the Korean stock market saw companies—backed not merely by fleeting thematic trends but by production certifications from global regulatory agencies, successful bids for government-funded research projects, and strong platform distribution performance—collectively rank among the top performers in terms of percentage gains, drawing significant market attention.

Osong Facility Receives U.S. and European Certification… Quratis Inc. Sets Sail as an Obesity CDMO

According to financial information provider KG Zeroin MP DOCTOR, the leading biotech stocks that entered the top 20 in overall gains on the domestic stock market that day were Quratis Inc.(348080), #MFC Co., Ltd., and BLUEMTEC CO., LTD.(439580). Compared to the previous trading day, Quratis Inc.’s stock price soared 30.00% to 3,705 won, hitting the daily price limit, while MFC Co., Ltd. also surged 29.96% to 3,145 won, settling at the upper price limit. BLUEMTEC CO., LTD., a pharmaceutical e-commerce specialist listed on the stock exchange, also posted a steep rally, closing at 2,600 won after a 14.54% gain.

Market experts analyze that companies possessing contract development and manufacturing (CDMO) capabilities, oral formulation technologies, and specialized distribution networks are benefiting structurally as production bottlenecks arise from increased demand for obesity treatments and as calls for improved convenience in medication administration grow. However, as the majority of stocks that surged today remain low-priced shares in the 2,000–3,000 won range, there is also a growing consensus that investors should be wary of volatility risks stemming from short-term supply-and-demand imbalances. Experts advise carefully evaluating fundamental strengths—such as actual cash generation capacity and financial soundness—to distinguish the wheat from the chaff.

Quratis Inc. soared to the daily price limit immediately after the market opened today, driven by the combined news of obtaining an on-site inspection certification from U.S. health authorities and expectations for the production of global treatments for obesity and metabolic diseases. The company received the final on-site inspection certificate for its Osong Bio Plant in North Chungcheong Province from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

This inspection was led by the departments responsible for AIDS (HIV) and tuberculosis research. The manufacturing quality control standards for all liquid and freeze-dried sterile injectables—including Quratis Inc.’s tuberculosis vaccine candidate—met the required criteria. The company is exploring contracts to supply vaccines and adjuvants for clinical trials in the U.S. and Europe.

Quratis Inc.’s Osong production facility has steadily enhanced its international credibility by securing certifications from leading global regulatory agencies one after another. Last July, it received approval for compliance with Current Good Manufacturing Practice (cGMP) standards from the U.S. Food and Drug Administration (FDA). Subsequently, it successfully completed an inspection by a Qualified Person (QP) under the European Union Good Manufacturing Practice (EU-GMP) standards.

Building on this momentum, the company partnered with Inventage Lab Inc.(389470), a platform company specializing in long-acting injectables, to begin full-scale biopharmaceutical production. The two companies have finalized unit price negotiations for key pipeline products—including treatments for dementia, obesity, and diabetes—and have begun full-scale manufacturing of clinical trial samples. Interest in contract manufacturing continues to grow, with European pharmaceutical companies and leading domestic biotech firms visiting the Osong plant to conduct on-site inspections.

A supply contract for an AIDS vaccine adjuvant previously signed with a U.S. biotech company also underscores the company’s manufacturing reliability. Quratis Inc. has built a stable manufacturing track record by supplying finished products to a global, multi-center clinical trial supported by U.S. health authorities.

Analysts in the securities industry assess that Quratis Inc.’s strategy—which involves reducing the risks associated with in-house new drug development while capitalizing on the shortage of injectable treatments for obesity and metabolic diseases faced by global pharmaceutical companies—has proven effective. There are forecasts that if the utilization rate of its biomanufacturing facility, which meets the regulatory standards of SUNJIN Co., Ltd., begins to rise significantly, the company will be able to shake off its chronic deficit structure and achieve a medium- to long-term turnaround.

A company official stated, “The completion of global certification for our Osong facility is proof that we have secured the trust of demanding overseas markets,” adding, “We will lay the groundwork for a leap in performance by expanding orders for high-value-added pharmaceuticals covering obesity and diabetes.”

MFC Co., Ltd. Leads 7.1 Billion Won Government-Funded Oral Insulin Project… Launches AI Formulation Platform

MFC Co., Ltd., a company specializing in high-value-added active pharmaceutical ingredients (APIs), saw its stock price soar to the daily upper limit after securing the lead role in a government-led project to develop next-generation oral insulin. The company announced on the 16th that it had been selected as the lead research and development institution for the “Customized Diagnostic and Therapeutic Products” sector under the Bio-Industry Technology Development Project, supported by the Ministry of Trade, Industry and Energy.

This project has a total budget of 7.1 billion won, with government funding alone amounting to 4.8 billion won. MFC Co., Ltd. will spearhead the development of an oral insulin finished pharmaceutical product—combining artificial intelligence (AI) and continuous manufacturing technology—for approximately 54 months, through December 2030.

Subcutaneous insulin injections, which require daily use of a syringe, suffer from very low patient compliance. However, due to the nature of protein substances, oral administration results in the drug being broken down by gastrointestinal digestive enzymes, and the low permeability of the intestinal mucosa has long made the development of oral medications an insurmountable challenge.

MFC Co., Ltd. has partnered with Kookmin University to utilize its proprietary peptide stabilization technology, which inhibits drug degradation in the gastrointestinal tract, along with absorption-enhancing design. The Dongguk University Industry-Academic Cooperation Foundation will be responsible for verifying nonclinical pharmacokinetics and bioavailability.

The company plans to utilize AI-based predictive models to reduce the time required for new drug discovery and process development by up to 50%. The company aims to complete preclinical evaluations by 2030, enter Phase 1 clinical trials, and secure a technology license-out (L/O) deal with a major global pharmaceutical company.

MFC Co., Ltd. has established a solid foothold based on its proprietary technology—the world’s first to crystallize a key intermediate for hyperlipidemia treatments into a solid form. To overcome the limitations of a business centered on generic drugs, the company introduced the active ingredient for ilaprazole, an improved new drug for gastroesophageal reflux disease (GERD) in the proton pump inhibitor (PPI) class. The company plans to successively launch active pharmaceutical ingredients for several high-margin improved new drugs, including the anti-inflammatory analgesic felubipropen.

The company is also accelerating its expansion into the global market. It is currently undergoing productivity verification to supply active pharmaceutical ingredients for hyperlipidemia treatments to a leading Japanese partner. Discussions regarding contract manufacturing (CMO) with domestic and international pharmaceutical companies are also expanding.

MFC Co., Ltd. emphasized, “We will complete the platform technology to convert diabetes treatments—which have been limited to injectables—into oral tablets,” adding, “Based on our AI-driven research capabilities in complex dosage forms, we will leap forward as a global digital pharmaceutical platform company.”

Hospital Distribution Platform Featuring ‘Wegovy’… BLUEMTEC CO., LTD. Kicks Off Path to Profitability by Adding Aesthetics

BLUEMTEC CO., LTD., the leading pharmaceutical e-commerce platform, posted double-digit growth driven by increased distribution of obesity treatments within medical institutions and the expansion of its high-margin aesthetic portfolio. BLUEMTEC CO., LTD., which operates “BluePharm Korea,” an e-commerce portal exclusively for hospitals and clinics, is regarded as a key gateway for the distribution of obesity treatments to private medical practices.

BLUEMTEC CO., LTD.’s revenue growth gained momentum as Novo Nordisk’s Wegovy, a global blockbuster obesity drug, began full-scale distribution to hospitals and clinics in Korea. Market estimates suggest that the company’s revenue from obesity treatment drug distribution alone reached approximately 50 billion won last year. Driven by this, total revenue for last year rose 39% year-over-year to 185.7 billion won. During the same period, the operating loss plummeted by 71% from 6.9 billion won to 2.0 billion won, dramatically reducing the deficit.

Leveraging a network of over 30,000 member hospitals and clinics nationwide—attracted by its proven “bait product,” the obesity treatment—BLUEMTEC CO., LTD. is now fully launching a high-margin aesthetic business. The company has partnered successively with Medy-Tox Inc.(086900) and Humedix Co., Ltd.(200670)to list its botulinum toxin and hyaluronic acid (HA) filler product lines on their platforms.

Medy-Tox Inc. is driving up average transaction value by distributing a wide range of in-clinic medical products, including Medy-Tox Inc.’s flagship filler lineup and injectables for submental fat reduction. According to market research firms, the global aesthetic market is a high-growth sector projected to exceed 200 trillion won by 2030.

BLUEMTEC CO., LTD. is expanding the scope of its platform beyond simple pharmaceutical delivery into the Medical Practice Management Support (MSO) sector. Recently, in collaboration with a marketing firm, it launched a solution for managing video advertisements in apartment building elevators near clinics, thereby launching a high-margin, platform-based advertising business model.

Analysts predict that the company is certain to return to profitability on an annual basis, as it has already surpassed its monthly break-even point (BEP) through the streamlining of selling, general, and administrative expenses (SG&A) and an increased share of high-margin products.

A BLUEMTEC CO., LTD. official explained, “Building on the platform’s proven strength in distributing obesity treatments, we are further strengthening our supply chain for aesthetic products such as fillers and botulinum toxin,” adding, “This year, we will simultaneously achieve scale expansion and solidify our foundation to deliver the best performance in the company’s history and achieve our first year of profitability.”

While experts view positively the fact that the companies whose stock prices surged today are aligned with strong global policy and consumer trends related to obesity and diabetes, they urge investors to refrain from excessive herd buying.

This is because every time news related to obesity treatments emerges, short-term thematic demand flows in, causing a recurring pattern of sharp stock price fluctuations. In particular, for low-priced stocks trading in the 2,000–3,000 won range, price volatility can become extremely high due to relatively low trading volume and profit-taking by institutional and foreign investors.

Hong Soon-jae, CEO of BioBook, advised, “There are many hurdles to overcome—such as stabilizing product yield, obtaining clinical trial approval, and ensuring sustained prescribing—before obesity treatment-related businesses can translate into actual operating profits.” He added, “Investors should make prudent investment decisions only after comprehensively reviewing a company’s fundamentals, including not only its development capabilities but also its immediately available cash and cash equivalents, debt-to-equity ratio, and ability to maintain profitability in its core business.”